Endocrine therapy – current benefits and limitations

@article{Nicholson2005EndocrineT,
  title={Endocrine therapy – current benefits and limitations},
  author={Robert Ian Nicholson and Stephen R. D. Johnston},
  journal={Breast Cancer Research and Treatment},
  year={2005},
  volume={93},
  pages={3-10}
}
Endocrine therapy is a valuable option for the treatment of postmenopausal women with estrogen receptor (ER)-positive breast cancer due to its demonstrated efficacy and favorable safety profile. Although tamoxifen has been the established treatment for more than 20 years its long-term use is associated with several tolerability concerns and may lead to increased risk of endometrial cancer and thromboembolic complications. In addition, many patients who initially respond to treatment with… CONTINUE READING
47 Citations
71 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 47 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 71 references

Results of the ATAC ( Arimidex , Tamoxifen , Alone or in Combination ) trial after completion of 5 years ’ adjuvant treatment for breast cancer

  • EP Winer, C Hudis, +18 authors GP Browman
  • Lancet
  • 2005

Evaluation of fulvestrant in women with advanced breast cancer and progression onprior aromatase inhibitor therapy : a phase II trial of the North Central Cancer Treatment Group

  • M Beato
  • BreastCancerResTreat
  • 2004

Similar Papers

Loading similar papers…